🚨 #ESMO26: Durvalumab’s first-line dominance in biliary tract cancer challenged!
HARMONi-GI1 | Phase III
Ivonescimab + GemCis vs Durvalumab + GemCis
🔥 OS: 14.9 vs 12.1 months (HR 0.75)
📈 PFS: 8.4 vs 5.8 months (HR 0.61)
🎯 ORR: 53.8% vs 32.5%
PD-1/VEGF bispecific therapy could redefine first-line BTC treatment.
@my_esmo @ESMO_open @ASCO @OncoAlert
15 views · 0 likes · 0 reposts · 0 replies
Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: The phase 3 randomized KEYNOTE-975 study
https://esmocongress.esmo.orgArcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.orgZanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgAnbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgFour months of adjuvant XELOX versus six months in stage II–IIIB gastric cancer: The LOMAC randomized trial
https://esmocongress.esmo.orgCLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade
https://esmocongress.esmo.org🚨 ESMO 2026 | TOP 10 GI CANCER TRIALS TO WATCH! From CLDN18.2 ADCs and PD-1/VEGF bispecifics to chemotherapy-free strategies, major GI oncology data are coming at #ESMO26! 🔥 My Top 10 Trials 🔴 GASTRIC / GEJ CANCER CLARITY-Gastric 01 (LBA7) | CLDN18.2 ADC vs investigator’s choice G-HOPE-001 (LBA77) | Novel CLDN18.2 ADC HERIZON-GEA-01 (LBA79) | Zanidatamab + chemotherapy ± tislelizumab GERCOR-GONO DEWI | Dostarlimab and nonoperative management in dMMR disease LOMAC (LBA81) | 4 vs 6 months of adjuvant CAPOX KC-WISE (LBA80) | Anbenitamab + chemotherapy RAMIRIS | FOLFIRI + ramucirumab vs paclitaxel + ramucirumab FORTITUDE-101/102 | FGFR2-targeted therapy and biomarker analysis 🟠 BILIARY TRACT CANCER HARMONi-GI1 (LBA8) | Ivonescimab + chemotherapy vs durvalumab + chemotherapy 🟣 ESOPHAGEAL / GEJ CANCER KEYNOTE-975 (2875O) | Pembrolizumab + definitive chemoradiotherapy ⭐ Two Presidential trials to watch closely: CLARITY-Gastric 01 and HARMONi-GI1. Which GI trial will have the greatest clinical impact? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #GICancer #Oncology在 X 查看被引用的帖子
Source: Dr Rishabh Jain · x.com